OMEROS CORPORATION
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $238.1M
- Website
- http://www.omeros.com/
Omeros Restructures $80.5 Million in Debt, Significantly Reducing Near-Term Financial Obligations
Omeros Corporation has entered into agreements to exchange $70.5 million of its 2026 Convertible Notes for new 2029 Convertible Notes with a 9.50% interest rate, extending debt maturity by three years.
IgA Nephropathy Pipeline Shows Robust Growth with 30+ Therapies in Development
DelveInsight's 2025 pipeline analysis reveals over 30 companies developing 30+ therapies for IgA nephropathy treatment, representing a robust therapeutic landscape.
Omeros Forms Elite Clinical Steering Committee to Advance Novel AML Therapeutic Program
Omeros Corporation has established an Oncology Clinical Steering Committee comprising eight distinguished leukemia experts from leading cancer centers to guide its OncotoX-AML program development.
Omeros Advances Zaltenibart Phase 3 Trials for PNH with Potential Superiority Over Current Treatments
Omeros Corporation has initiated site activation for its Phase 3 clinical trials of zaltenibart (OMS906) in paroxysmal nocturnal hemoglobinuria (PNH), with data for regulatory submission expected in Q4 2026.
Narsoplimab Shows Promising Real-World Outcomes in TA-TMA Patients at 2025 Tandem Meetings
Omeros Corporation will present real-world data from 128 transplant patients treated with narsoplimab for TA-TMA under an expanded access program at the 2025 Tandem Meetings in Honolulu.